ロード中...
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of April, 2020, over 3 million people had been confirmed infected, with over 1 million in the USA alone, and over 215 000 dea...
保存先:
| 出版年: | Lancet Respir Med |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier Ltd.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7228727/ https://ncbi.nlm.nih.gov/pubmed/32422178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(20)30225-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|